Aquatic Capital Management’s Denali Therapeutics DNLI Stock Holding History

Aquatic Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-56,237	Closed	-$817K	–	1472
2025 Q3	$817K	Buy	+56,237	New	+$808K	0.02%	733
2025 Q1	–	Sell	-15,694	Closed	-$320K	–	1336
2024 Q4	$320K	Buy	+15,694	New	+$402K	0.01%	831
2024 Q1	–	Sell	-8,300	Closed	-$178K	–	1308
2023 Q4	$178K	Sell	8,300 -10,000	-55%	-$198K	﹤0.01%	873
2023 Q3	$378K	Buy	18,300 +16,300	+815%	+$413K	0.02%	541
2023 Q2	$59K	Sell	2,000 -1,800	-47%	-$50.6K	﹤0.01%	957
2023 Q1	$88K	Buy	+3,800	New	+$105K	0.01%	778
2022 Q2	–	Sell	-1,100	Closed	-$35K	–	1278
2022 Q1	$35K	Buy	+1,100	New	+$37.9K	0.05%	358

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aquatic Capital Management's DNLI Position: Q4 2025 in Review

Aquatic Capital Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 56,237 shares — an estimated $817K sold.

Aquatic Capital Management first reported a position in DNLI in Q1 2022 and held it in 7 quarters. The position peaked at $817K in Q3 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Aquatic Capital Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Aquatic Capital Management sold 56,237 Denali Therapeutics shares in Q4 2025, an estimated $817K.
Aquatic Capital Management first reported a position in Denali Therapeutics in Q1 2022 and held it in 7 quarters.
Aquatic Capital Management's Denali Therapeutics position peaked at $817K in Q3 2025.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Aquatic Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.